Patents by Inventor Eric Labonte

Eric Labonte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
    Publication number: 20210186953
    Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
    Type: Application
    Filed: December 30, 2020
    Publication date: June 24, 2021
    Applicant: Ardelyx, Inc.
    Inventors: Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
  • NHE3-binding compounds and methods for inhibiting phosphate transport
    Patent number: 10940146
    Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 9, 2021
    Assignee: Ardelyx, Inc.
    Inventors: Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
  • NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
    Publication number: 20190275028
    Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 12, 2019
    Applicant: Ardelyx, Inc.
    Inventors: Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
  • NHE3-binding compounds and methods for inhibiting phosphate transport
    Patent number: 10272079
    Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: April 30, 2019
    Assignee: ARDELYX, INC.
    Inventors: Christopher Carreras, Dominique Charmot, Jeffrey W Jacobs, Eric Labonte, Jason G. Lewis
  • Compositions and methods for treating hyperkalemia
    Patent number: 9919006
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 20, 2018
    Assignee: Ardelyx, Inc.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA
    Publication number: 20180064751
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: April 14, 2017
    Publication date: March 8, 2018
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Compositions and methods for treating hyperkalemia
    Patent number: 9867848
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: January 16, 2018
    Assignee: ARDELYX, INC.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA
    Publication number: 20170196903
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA
    Publication number: 20170173072
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: July 29, 2016
    Publication date: June 22, 2017
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Compositions and methods for treating hyperkalemia
    Patent number: 9655921
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: May 23, 2017
    Assignee: Ardelyx, Inc.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
    Publication number: 20170037010
    Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: February 19, 2016
    Publication date: February 9, 2017
    Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
  • Pharmaceutical compositions for treating hyperkalemia
    Patent number: 9549947
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: January 24, 2017
    Assignee: Ardelyx, Inc.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Pharmaceutical compositions for treating hyperkalemia
    Patent number: 9545425
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: January 17, 2017
    Assignee: Ardelyx, Inc.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA
    Publication number: 20160346318
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 1, 2016
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Compositions and methods for treating hyperkalemia
    Patent number: 9433640
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: September 6, 2016
    Assignee: Ardelyx, Inc.
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA
    Publication number: 20160175346
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: February 24, 2016
    Publication date: June 23, 2016
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • PHARMACEUTICAL COMPOSITIONS FOR TREATING HYPERKALEMIA
    Publication number: 20160175345
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: February 24, 2016
    Publication date: June 23, 2016
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • COMPOSITIONS AND METHODS FOR TREATING HYPERKALEMIA
    Publication number: 20160175344
    Abstract: The present invention is directed to compositions and methods of removing potassium or treating hyperkalemia by administering pharmaceutical compositions of cation exchange polymers with low crosslinking for improved potassium excretion and for beneficial physical properties to increase patient compliance.
    Type: Application
    Filed: February 24, 2016
    Publication date: June 23, 2016
    Inventors: Dominique Charmot, James P. Davidson, Fangling Lin, Jeffrey W. Jacobs, Natalia Blinova, Eric Labonte, Ingrid Langsetmo, Robert C. Blanks
  • Compounds and methods for inhibiting phosphate transport
    Patent number: 9301951
    Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, A, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: April 5, 2016
    Assignee: Ardelyx, Inc.
    Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
  • Compounds and methods for inhibiting phosphate transport
    Patent number: 9289429
    Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 22, 2016
    Assignee: Ardelyx, Inc.
    Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte